LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

Search

Erasca Inc

Aperta

1.7 4.94

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.62

Massimo

1.74

Metriche Chiave

By Trading Economics

Entrata

-2.9M

-34M

Margine di Profitto

-768.16

Dipendenti

103

EBITDA

-2.5M

-38M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+103.13% upside

Dividendi

By Dow Jones

Utili prossimi

10 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

35M

454M

Apertura precedente

-3.24

Chiusura precedente

1.7

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Erasca Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

16 set 2025, 17:03 UTC

I principali Market Mover

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 set 2025, 16:49 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

GD Culture Shares Drop After Deal for Pallas Capital

16 set 2025, 16:11 UTC

I principali Market Mover

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 set 2025, 23:40 UTC

Discorsi di Mercato

Nikkei May Decline as Yen Strengthens -- Market Talk

16 set 2025, 23:34 UTC

Discorsi di Mercato

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 set 2025, 23:20 UTC

Discorsi di Mercato

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 set 2025, 21:10 UTC

Acquisizioni, Fusioni, Takeovers

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 set 2025, 20:51 UTC

Discorsi di Mercato

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 set 2025, 20:50 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

16 set 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

16 set 2025, 20:25 UTC

Utili

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 set 2025, 20:24 UTC

Utili

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 set 2025, 19:19 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 set 2025, 18:52 UTC

Discorsi di Mercato

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 set 2025, 18:44 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

16 set 2025, 18:44 UTC

Discorsi di Mercato

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 set 2025, 18:40 UTC

Acquisizioni, Fusioni, Takeovers

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 set 2025, 18:38 UTC

Discorsi di Mercato

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 set 2025, 18:19 UTC

Discorsi di Mercato

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 set 2025, 18:01 UTC

Discorsi di Mercato

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 set 2025, 17:34 UTC

Discorsi di Mercato

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 set 2025, 16:53 UTC

Utili

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 set 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

16 set 2025, 16:15 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Commodities Roundup: Market Talk

16 set 2025, 16:09 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Energy Roundup: Market Talk

16 set 2025, 16:09 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 set 2025, 15:35 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

16 set 2025, 15:35 UTC

Discorsi di Mercato

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 set 2025, 15:22 UTC

Discorsi di Mercato

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 set 2025, 15:21 UTC

Discorsi di Mercato

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Confronto tra pari

Modifica del prezzo

Erasca Inc Previsione

Obiettivo di Prezzo

By TipRanks

103.13% in crescita

Previsioni per 12 mesi

Media 3.25 USD  103.13%

Alto 6 USD

Basso 1 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Erasca Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

4 ratings

2

Acquista

1

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

1.39 / 1.44Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Very Strong Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
help-icon Live chat